Profound Medical (PROF) Price & Analysis

80 Followers

PROF Stock Chart & Stats

$7.26

$0.41(5.99%)

At close: Jul 24 4:00 PM EDT

$7.26

$0.41(5.99%)

Day’s Range― - ―

52-Week Range$3.76 - $8.95

Previous CloseN/A

Volume272.42K

Average Volume (3M)136.84K

Market Cap

$247.96M

Enterprise Value$298.96

Total Cash (Recent Filing)$38.21M

Total Debt (Recent Filing)$7.37M

Price to Earnings (P/E)―

Beta0.86

Next Earnings

Oct 29, 2026

EPS Estimate

-0.23

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.97

Shares Outstanding36,532,593

10 Day Avg. Volume105,290

30 Day Avg. Volume136,840

Financial Highlights & Ratios

PEG Ratio-0.20

Price to Book (P/B)3.58

Price to Sales (P/S)14.48

P/FCF Ratio-6.07

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$11.00

Price Target Upside51.52% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)-0.6

Revenue Forecast (FY)$18.52M

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth And PipelineRapid revenue growth, an 84-system installed base, and a substantial qualified pipeline support continued expansion. Converting pipeline opportunities into installations and procedures could build both equipment and recurring consumables revenue over the next several quarters.

High Gross Margins And Expense DisciplineHealthy gross margins indicate attractive economics for the medical-device platform, while lower operating expenses show improving cost discipline. If revenue scales through the installed base, these trends could provide operating leverage and narrow losses over time.

Reimbursement And Clinical DifferentiationFavorable proposed hospital reimbursement and strong clinical outcomes can improve provider economics and support adoption. Better urinary and sexual-function results may differentiate TULSA from surgery and competing ablation approaches in prostate care.

Bears Say

Deep Losses And Heavy Cash BurnThe company remains far from profitability and consumes substantial cash, with burn worsening versus the prior period. Continued commercialization investment may require external financing before scale produces sufficient gross profit to fund operations internally.

Installation Delays And Variable ConversionLong installation cycles and shipment timing issues delay revenue recognition and procedure ramp-up after orders are secured. These execution constraints make quarterly results less predictable and could slow conversion of the qualified pipeline into recurring utilization.

Proposed ASC Reimbursement ReductionA lower ambulatory-surgery-center payment could weaken provider economics and limit adoption in that setting if finalized. Although Profound currently has no active ASC sites, the proposal may constrain a future channel for procedure growth and diversification.

Profound Medical News

Profound Medical CFO Rashed Dewan steps down, Matthew Sobczyk interim CFO

Profound Medical (PROF) announced the promotion of Matthew Sobczyk from Corporate Controller to Interim CFO, effective immediately. Sobczyk,...

12d ago

PROF

Profound Medical Launches Enhanced TULSA-PRO Software Upgrade

Profound Medical ( ($TSE:PRN) ) has issued an announcement. On August 17, 2026, Profound Medical introduced a new...

11d ago

PROF

Profound Medical Names Interim CFO Amid Leadership Transition

Profound Medical ( ($TSE:PRN) ) has issued an update. Profound Medical Corp. announced on August 14, 2026 that...

11d ago

PROF

Profound Medical Earnings Call Highlights Growth Momentum

Profound Medical (($TSE:PRN)) has held its Q2 earnings call. Read on for the main highlights of the call....

12d ago

PROF

Profound Medical Launches Global Prostate Patient Advocacy Community

Profound Medical ( ($TSE:PRN) ) has issued an update. On August 13, 2026, Profound Medical launched Let’s Huddle,...

14d ago

PROF

Analyst Reaffirms Buy on TULSA Maker as Deferred Shipments, Record Orders and Strong 2H Outlook Signal Robust Underlying Growth

Raymond James analyst Michael W. Freeman has maintained their bullish stance on PRN stock, giving a Buy rating...

18d ago

PROF

Profound Medical Boosts Orders, Narrows Loss as TULSA Adoption and Coverage Expand

An update from Profound Medical ( ($TSE:PRN) ) is now available. Profound Medical reported second-quarter 2026 results marked...

21d ago

PROF

Profound Medical upgraded to Strong Buy from Outperform at Raymond James

Raymond James upgraded Profound Medical (PROF) to Strong Buy from Outperform with an unchanged price target of $11....

1M ago

PROF

Profound Medical upgraded to Strong Buy at Raymond James after positive data

As previously reported, Raymond James analyst Michael Freeman upgraded Profound Medical (PROF) to Strong Buy from Outperform with...

1M ago

PROF

Profound Medical Highlights New TULSA Quality-of-Life Data

Profound Medical ( ($TSE:PRN) ) has provided an update. On July 24, 2026, Profound Medical reported new data...

1M ago

PROF

Source Rock Royalties Declares Monthly Dividend and Issues Incentive RSUs

Profound Medical ( ($TSE:PRN) ) has shared an announcement. Source Rock Royalties Ltd. declared a monthly cash dividend...

1M ago

PROF

Profound Medical Shareholders Back Board, Question Incentive Plan

An announcement from Profound Medical ( ($TSE:PRN) ) is now available. At its Annual General and Special Meeting...

3M ago

PROF

Telix announces LoI to collaborate with EDAP TMS and Profound Medical

Telix Pharmaceuticals (TLX) announces that it has entered into letters of intent, or LoI, to pursue collaborations with...

3M ago

EDAP

PROF

Profound Medical Highlights TULSA Advances at AUA 2026

Profound Medical ( ($TSE:PRN) ) has provided an update. On May 14, 2026, Profound Medical announced that its...

4M ago

PROF

PROF FAQ

What was Profound Medical’s price range in the past 12 months?

Profound Medical lowest stock price was $3.76 and its highest was $8.95 in the past 12 months.

What is Profound Medical’s market cap?

Profound Medical’s market cap is $247.96M.

When is Profound Medical’s upcoming earnings report date?

Profound Medical’s upcoming earnings report date is Oct 29, 2026 which is in 62 days.

How were Profound Medical’s earnings last quarter?

Profound Medical released its earnings results on Aug 06, 2026. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.242 by -$0.018.

Is Profound Medical overvalued?

According to Wall Street analysts Profound Medical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Profound Medical pay dividends?

Profound Medical does not currently pay dividends.

What is Profound Medical’s EPS estimate?

Profound Medical’s EPS estimate is -0.23.

How many shares outstanding does Profound Medical have?

Profound Medical has 36,532,593 shares outstanding.

What happened to Profound Medical’s price movement after its last earnings report?

Profound Medical reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.242. Following the earnings report the stock price went down -6.675%.

Which hedge fund is a major shareholder of Profound Medical?

Currently, no hedge funds are holding shares in PROF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Profound Medical Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

30.60%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Profound Medical

Profound Medical Corp., along with its subsidiaries, operates as a commercial-stage medical technology firm. The company specializes in creating magnetic resonance (MR) guided ablation therapies designed to address prostate conditions, uterine fibroids, and to provide palliative pain management. Its market reach extends to Canada, Germany, the United States, and Finland. The company's primary offering is the TULSA-PRO system, which is engineered to integrate with magnetic resonance imaging (MRI) scanners within hospitals and clinical treatment facilities. Additionally, Profound Medical offers Sonalleve, a versatile therapeutic platform that treats uterine fibroids, delivers palliative pain relief for bone metastases, and provides non-invasive solutions for uterine fibroid treatment. Profound Medical Corp. maintains its corporate headquarters in Mississauga, Canada.

Profound Medical (PROF) Earnings & Revenues

Historic Earnings Reports

PROF Stock 12 Month Forecast

Average Price Target

$11.00

▲(51.52% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","8":"$8","13":"$13","5.5":"$5.5","10.5":"$10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$11.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,5.5,8,10.5,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.38,7.735384615384615,8.090769230769231,8.446153846153846,8.801538461538462,9.156923076923077,9.512307692307692,9.867692307692309,10.223076923076924,10.57846153846154,10.933846153846154,11.28923076923077,11.644615384615385,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.38,7.658461538461538,7.936923076923077,8.215384615384615,8.493846153846153,8.772307692307692,9.05076923076923,9.329230769230769,9.607692307692307,9.886153846153846,10.164615384615384,10.443076923076923,10.721538461538461,{"y":11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.38,7.581538461538462,7.783076923076923,7.984615384615385,8.186153846153847,8.387692307692308,8.589230769230769,8.79076923076923,8.992307692307692,9.193846153846154,9.395384615384614,9.596923076923076,9.798461538461538,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.94,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.07,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.42,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.87,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.76,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.46,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.53,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.86,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.67,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.75,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.38,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >